183 related articles for article (PubMed ID: 33712534)
21.
García Vicente AM; Talavera Rubio MP; Dominguez Ferreras E; Calle Primo C; Amo-Salas M; Tello Galán MJ; Jiménez Londoño GA; Jiménez Aragón F; Hernández Ruiz B; Soriano Castrejón Á
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(3):151-155. PubMed ID: 29107751
[TBL] [Abstract][Full Text] [Related]
22. Value of fusion of PET and MRI for staging of endometrial cancer: comparison with ¹⁸F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI.
Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Takahashi S; Ebina Y; Miyahara Y; Yamada H; Sugimura K
Eur J Radiol; 2013 Oct; 82(10):1672-6. PubMed ID: 23727380
[TBL] [Abstract][Full Text] [Related]
23.
Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma.
Pinilla I; Gómez-León N; Del Campo-Del Val L; Hernandez-Maraver D; Rodríguez-Vigil B; Jover-Díaz R; Coya J
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):567-75. PubMed ID: 21150860
[TBL] [Abstract][Full Text] [Related]
25. Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer.
de Jong TL; Koopman D; van der Worp CAJ; Stevens H; Vuijk FA; Vahrmeijer AL; Mieog JSD; de Groot JB; Meijssen MAC; Nieuwenhuijs VB; Lioe-Fee GO; Jager PL; Patijn GA
Surg Oncol; 2023 Apr; 47():101909. PubMed ID: 36739788
[TBL] [Abstract][Full Text] [Related]
26.
Verhagen MV; Menezes LJ; Neriman D; Watson TA; Punwani S; Taylor SA; Shankar A; Daw S; Humphries PD
J Nucl Med; 2021 Nov; 62(11):1524-1530. PubMed ID: 33608429
[TBL] [Abstract][Full Text] [Related]
27. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
Liu Y
Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
[TBL] [Abstract][Full Text] [Related]
28. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas.
Wu HB; Wang QS; Wang MF; Li HS; Zhou WL; Ye XH; Wang QY
Nucl Med Commun; 2010 Mar; 31(3):195-200. PubMed ID: 20009963
[TBL] [Abstract][Full Text] [Related]
29. Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CT.
Chiaravalloti A; Danieli R; Caracciolo CR; Travascio L; Cantonetti M; Gallamini A; Guazzaroni M; Orlacchio A; Simonetti G; Schillaci O
Medicine (Baltimore); 2014 Aug; 93(8):e50. PubMed ID: 25121354
[TBL] [Abstract][Full Text] [Related]
30.
He L; Chen Y; Tan X; Sun X; Zhang Q; Luo H; Jiang L
Jpn J Radiol; 2023 Jan; 41(1):98-107. PubMed ID: 35895223
[TBL] [Abstract][Full Text] [Related]
31. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
Ömür Ö; Baran Y; Oral A; Ceylan Y
Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
[TBL] [Abstract][Full Text] [Related]
32. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
33. [Is ceCT necessary beyond FDG-PET/CT for primary staging in Hodgkin lymphoma?].
Kajáry K; Molnár Z; Szakáll S; Molnár P; Lengyel Z
Orv Hetil; 2014 Feb; 155(6):226-30. PubMed ID: 24486846
[TBL] [Abstract][Full Text] [Related]
34. Limited benefit of additional contrast-enhanced CT to end-of-treatment PET/CT evaluation in patients with follicular lymphoma.
Paone G; Raditchkova-Sarnelli M; Ruberto-Macchi T; Cuzzocrea M; Zucca E; Ceriani L; Giovanella L
Sci Rep; 2021 Sep; 11(1):18496. PubMed ID: 34531504
[TBL] [Abstract][Full Text] [Related]
35. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas.
Niccoli-Asabella A; Altini C; Notaristefano A; Merenda N; Altieri ML; Stabile-Ianora AA; Fanelli M; Rubini G
Nucl Med Commun; 2013 Jan; 34(1):32-9. PubMed ID: 23111380
[TBL] [Abstract][Full Text] [Related]
36. Clinical impact of contrast-enhanced computed tomography combined with low-dose (18)F-fluorodeoxyglucose positron emission tomography/computed tomography on routine lymphoma patient management.
Chalaye J; Luciani A; Enache C; Beaussart P; Lhermite C; Evangelista E; Sasanelli M; Safar V; Meignan M; Haioun C; Rahmouni A; Itti E
Leuk Lymphoma; 2014 Dec; 55(12):2887-92. PubMed ID: 24597987
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of non
Sheldon JA; Yap KK; Taubman KL; Schlicht SM
J Med Imaging Radiat Oncol; 2018 Apr; 62(2):194-202. PubMed ID: 29230956
[TBL] [Abstract][Full Text] [Related]
38. The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients.
Nanni C; Zompatori M; Ambrosini V; Montesi V; Mezzetti S; Ferretti A; Chondrogiannis S; Rubello D; Fanti S
Biomed Pharmacother; 2013 Mar; 67(2):172-8. PubMed ID: 23433901
[TBL] [Abstract][Full Text] [Related]
39. Fluorodeoxyglucose-positron emission tomography/computed tomography performs better than contrast-enhanced computed tomography for metastasis evaluation in the initial staging of pancreatic adenocarcinoma.
Santhosh S; Mittal BR; Bhasin DK; Rana SS; Gupta R; Das A; Nada R
Ann Nucl Med; 2017 Oct; 31(8):575-581. PubMed ID: 28689356
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
